TLDR: Strategy expands its Stream Preferred Stock deal from €350M to €620M. Funds will support Bitcoin purchases and general operations. The STRE stock offers a 10% annual dividend, compounded if unpaid. Settlement of the €620M offering is set for November 13, 2025. Strategy Inc (Nasdaq: MSTR) announced the pricing of its €620 million Stream Perpetual [...] The post Strategy Upsizes Stream Stock to €620M to Fuel Bitcoin Buys appeared first on Blockonomi.TLDR: Strategy expands its Stream Preferred Stock deal from €350M to €620M. Funds will support Bitcoin purchases and general operations. The STRE stock offers a 10% annual dividend, compounded if unpaid. Settlement of the €620M offering is set for November 13, 2025. Strategy Inc (Nasdaq: MSTR) announced the pricing of its €620 million Stream Perpetual [...] The post Strategy Upsizes Stream Stock to €620M to Fuel Bitcoin Buys appeared first on Blockonomi.

Strategy Upsizes Stream Stock to €620M to Fuel Bitcoin Buys

TLDR:

  • Strategy expands its Stream Preferred Stock deal from €350M to €620M.
  • Funds will support Bitcoin purchases and general operations.
  • The STRE stock offers a 10% annual dividend, compounded if unpaid.
  • Settlement of the €620M offering is set for November 13, 2025.

Strategy Inc (Nasdaq: MSTR) announced the pricing of its €620 million Stream Perpetual Preferred Stock offering, expanding from an initial €350 million target. The company priced 7.75 million shares of its 10% Series A Stream Preferred Stock (STRE) at €80 per share. 

Settlement is scheduled for November 13, 2025, pending customary closing conditions. The firm expects net proceeds of about €608.8 million, according to its official release.

Funds Target Bitcoin Acquisition and Corporate Expansion

According to the company’s statement, proceeds from the offering will be used for general corporate purposes, including Bitcoin acquisitions and working capital. This move aligns with Strategy’s ongoing crypto investment strategy, widely associated with Michael Saylor’s continued focus on digital asset accumulation.

Based on Bloomberg’s €1.00/$1.1534 exchange rate, the proceeds equal roughly $715.1 million in gross capital raised.

The STRE Stock carries a 10% annual dividend rate, paid quarterly in arrears beginning December 31, 2025. Dividends will be distributed in cash when declared by the board, with compounded dividends applied to any unpaid amounts. 

The compounded rate can rise by 100 basis points per quarter if deferred, capped at 18% annually.

Dividend and Redemption Terms Outline a Long-Term Strategy

If Strategy fails to declare dividends by the record date, it will issue a notice of deferral and may sell other securities to cover missed payments. These may include the company’s Stride, Strike, or Strife preferred stock series, alongside other equity classes. The firm retains the right to redeem all outstanding STRE shares if their total falls below 25% of initial issuance or if certain tax events occur.

The redemption price equals the liquidation preference per share plus accrued dividends. The liquidation preference starts at €100 per share but can adjust daily based on trading activity or market pricing. Such flexibility allows the firm to maintain alignment with market value fluctuations.

Barclays, Morgan Stanley, Moelis & Company, SG Americas Securities, TD Securities, Canaccord Genuity, and StoneX Financial are acting as joint book-running managers for the offering. 

The company’s offering will not target retail investors within the European Economic Area or the U.K. Regulatory filings confirm that sales are restricted to professional and institutional investors under regional securities laws. The move ensures compliance with the Prospectus and PRIIPs regulations governing financial offerings in both markets.

The post Strategy Upsizes Stream Stock to €620M to Fuel Bitcoin Buys appeared first on Blockonomi.

Market Opportunity
Streamflow Logo
Streamflow Price(STREAM)
$0.01629
$0.01629$0.01629
-0.36%
USD
Streamflow (STREAM) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26